188 related articles for article (PubMed ID: 35599247)
1. Successful treatment of induced oligometastasis and repeated oligoprogression of advanced lung adenocarcinoma with immunotherapy and radiotherapy.
Lee HY; Kim SH; Lee HY; Lee YM; Han JY; Cho H; Lee HK
Thorac Cancer; 2022 Jul; 13(13):1998-2000. PubMed ID: 35599247
[TBL] [Abstract][Full Text] [Related]
2. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
[TBL] [Abstract][Full Text] [Related]
3. Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma.
Yang G; Kim KH; Lee CG; Hong MH; Kim HR; Cho Y; Yoon HI
Cancer Res Treat; 2024 Jan; 56(1):115-124. PubMed ID: 37641819
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
5. American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer.
Amini A; Verma V; Simone CB; Chetty IJ; Chun SG; Donington J; Edelman MJ; Higgins KA; Kestin LL; Movsas B; Rodrigues GB; Rosenzweig KE; Rybkin II; Slotman BJ; Wolf A; Chang JY
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):361-375. PubMed ID: 34571054
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis.
Onal C; Gultekin M; Oymak E; Guler OC; Yilmaz MT; Yuce Sari S; Akkus Yildirim B; Yildiz F
Int J Gynecol Cancer; 2020 Jun; 30(6):865-872. PubMed ID: 32273293
[TBL] [Abstract][Full Text] [Related]
7. Role of radiation in oligometastases and oligoprogression in metastatic non-small cell lung cancer: consensus and controversy.
Kumar A; Salama JK
Expert Rev Respir Med; 2023; 17(11):1033-1040. PubMed ID: 37962878
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic options for oligoprogressive non-small cell lung cancer].
Gustin P; Botticella A; Tselikas L; Mercier O; Le Péchoux C; Levy A
Rev Mal Respir; 2019 Apr; 36(4):519-526. PubMed ID: 31010758
[TBL] [Abstract][Full Text] [Related]
9. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
Dohopolski M; Iyengar P
Ann Palliat Med; 2021 May; 10(5):5944-5953. PubMed ID: 33691460
[TBL] [Abstract][Full Text] [Related]
10. Optimize Local Therapy for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer to Enhance Survival.
Chang JY; Verma V
J Natl Compr Canc Netw; 2022 May; 20(5):531-539. PubMed ID: 35545175
[TBL] [Abstract][Full Text] [Related]
11. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Kim C; Hoang CD; Kesarwala AH; Schrump DS; Guha U; Rajan A
J Thorac Oncol; 2017 Feb; 12(2):179-193. PubMed ID: 27780780
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
[TBL] [Abstract][Full Text] [Related]
13. The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review.
Turchan WT; Chmura SJ
Ann Palliat Med; 2021 May; 10(5):6028-6044. PubMed ID: 33440982
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
Xuzhang W; Huang H; Yu Y; Shen L; Li Z; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231156387. PubMed ID: 36895853
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival of a patient with programmed death ligand 1-negative lung adenocarcinoma and oligoprogressive disease treated with nivolumab and stereotactic body radiation therapy.
Sotelo MJ; Cabezas-Camarero S; Riquelme A; Bueno C
J Cancer Res Ther; 2020; 16(4):941-945. PubMed ID: 32930148
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
[TBL] [Abstract][Full Text] [Related]
17. [Radiotherapy for oligometastatic non-small cell lung cancer patients].
Levy A; Roux C; Mercier O; Issard J; Botticella A; Barlesi F; Le Péchoux C
Cancer Radiother; 2021 Oct; 25(6-7):517-522. PubMed ID: 34175225
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of oligometastatic or oligoprogression cancer].
Bourgier C; Latorzeff I; Fenoglietto P; Boisselier P; Charissoux M; Llacer C; Lemanski C; Riou O; Farcy-Jacquet MP; Azria D
Cancer Radiother; 2019 Oct; 23(6-7):482-485. PubMed ID: 31495737
[TBL] [Abstract][Full Text] [Related]
19. Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies.
Jongbloed M; Khosla AA; Bartolomeo V; Jatwani K; Singh R; De Ruysscher DKM; Hendriks LEL; Desai A
Curr Oncol Rep; 2024 Jan; 26(1):80-89. PubMed ID: 38175464
[TBL] [Abstract][Full Text] [Related]
20. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Jairam V; Park HS; Decker RH
Cancer J; 2020; 26(2):129-136. PubMed ID: 32205537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]